Round Up

Five things for pharma marketers to know: Tuesday, April 25, 2017

Five things for pharma marketers to know: Tuesday, April 25, 2017

By

Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Five things for pharma marketers to know: Wednesday, April 19, 2017

Five things for pharma marketers to know: Wednesday, April 19, 2017

By

Valeant gave $100,000 to patient group to address affordability of its drug; Omnicom reports 3% increase in specialty group revenue; Verily to study biometric data

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

By

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

By

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

By

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

By

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

By

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Five things for pharma marketers to know: Tuesday, March 28, 2017

Five things for pharma marketers to know: Tuesday, March 28, 2017

By

Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results

Five things for pharma marketers to know: Thursday, March 23, 2017

Five things for pharma marketers to know: Thursday, March 23, 2017

By

AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

By

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Five things for pharma marketers to know: Thursday, March 9, 2017

Five things for pharma marketers to know: Thursday, March 9, 2017

Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

By

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies

Five things for pharma marketers to know: Monday, February 27, 2017

Five things for pharma marketers to know: Monday, February 27, 2017

By

Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

By

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Five things for pharma marketers to know: Wednesday, February 22, 2017

Five things for pharma marketers to know: Wednesday, February 22, 2017

By

Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead

Five things for pharma marketers to know: Wednesday, February 8, 2017

Five things for pharma marketers to know: Wednesday, February 8, 2017

By

Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say

Five things for pharma marketers to know: Wednesday, February 1, 2017

Five things for pharma marketers to know: Wednesday, February 1, 2017

By

Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial

Five things for pharma marketers to know: Friday January 27, 2017

Five things for pharma marketers to know: Friday January 27, 2017

By

BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup

Five things for pharma marketers to know: Monday, January 23, 2017

Five things for pharma marketers to know: Monday, January 23, 2017

By

BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA

Five things for pharma marketers to know: Thursday, January 19, 2017

Five things for pharma marketers to know: Thursday, January 19, 2017

By

The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma

 Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

By

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

By

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Five things for pharma marketers to know: Thursday, January 5, 2017

Five things for pharma marketers to know: Thursday, January 5, 2017

By

Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales

Five things for pharma marketers to know: Thursday, December 22, 2016

Five things for pharma marketers to know: Thursday, December 22, 2016

By

Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"

Five things for pharma marketers to know: Tuesday, December 20, 2016

Five things for pharma marketers to know: Tuesday, December 20, 2016

By

Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

By

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

Five things for pharma marketers to know: Monday, October 31, 2016

Five things for pharma marketers to know: Monday, October 31, 2016

By

Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed

Five things for pharma marketers to know: Wednesday, October 26, 2016

Five things for pharma marketers to know: Wednesday, October 26, 2016

By

Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

OPINION

Newsletters